Gilead Sciences and Kite to Acquire Cell Design Labs
Gilead Sciences, Inc. (Nasdaq: GILD) and its cell therapy subsidiary Kite announced today that they have entered into a definitive agreement under which they have agreed to acquire Cell Design Labs, Inc., gaining new technology platforms that will enhance research and development efforts in cellular therapy. Under the terms of the agreement, Gilead will acquire all of the outstanding shares of Cell Design Labs, which includes the approximately 12.2 percent of shares of Cell Design Labs that are currently held by Kite, for up to approximately $567 million. The agreement includes an initial upfront payment of approximately $175 million, subject to certain adjustments, and additional payments of up to $322 million that will be paid to the shareholders of Cell Design Labs other than Kite upon the occurrence of certain events, including the achievement of development and approval milestones. The acquisition is subject to customary closing conditions, and is expected to close shortly.
The transaction will build on Gilead’s recent acquisition of Kite Pharma, Inc. and has the potential to help the Gilead and Kite organizations accelerate the development of next generation cellular therapy candidates.
Cell Design Labs is a pre-clinical stage company with significant expertise in custom cell engineering. The company is developing two propriety technology platforms: synNotch™, a synthetic gene expression system that responds to external cues which, among other applications, can be deployed to engineer chimeric antigen receptor T (CAR T) cells that require dual antigen recognition for activation, and Throttle™, an “on switch” that modulates CAR T activity using small molecules. The addition of these technologies to existing Kite research and development programs could lead to the treatment of a broader range of hematological malignancies and solid tumors, and potentially offer improved selectivity and safety of future treatments. Additionally, Cell Design Labs is developing several pre-clinical product candidates, including therapies for prostate cancer and hepatocellular carcinoma that use the synNotch technology. The company’s lead pre-clinical candidate targets multiple myeloma.
“We are excited about the potential of the synNotch and Throttle technology platforms and the application of these technologies to complement ongoing Kite research and development efforts,” said John F. Milligan, PhD, Gilead’s President and Chief Executive Officer. “This acquisition demonstrates our deep commitment to continuing to invest in future innovation in the field of cellular therapy, both internally and externally. Cell Design Labs’ talented team of cell biology experts will augment and accelerate our work to bring forward new generations of CAR T and TCR therapies, building on our acquisition of Kite earlier this year and our efforts to improve care for people with advanced cancers.”
“Our growing understanding of molecular networks now allows us to engineer cells with novel behaviors, including therapeutic immune cells programmed to precisely recognize and treat cancer,” said Wendell Lim, PhD, Scientific Founder, Cell Design Labs and Chair of the Department of Cellular and Molecular Pharmacology at the University of California, San Francisco. “This transaction has the potential to significantly advance the field, ultimately leading to the development of transformative treatments for cancer and other complex diseases.”
“Gilead and Kite have the expertise, resources and infrastructure to help deliver on our vision of using the body’s own immune system to develop powerful living therapies,” said Fred Cohen, MD, PhD, Chairman of the Board of Directors for Cell Design Labs. “We believe that by becoming part of the Gilead and Kite organizations, we will be better able to advance a new class of cell-based therapies to help people for generations to come.”
Cell Design Labs’ investors, led by Kleiner Perkins, also included Kite, Osage Ventures, Mission Bay Ventures, Brian Atwood, President, Chief Executive Officer and Co-Founder of Cell Design Labs, Kite founder and member of the Cell Design Labs Board of Directors, Arie Belldegrun, MD, as well as other investors with significant experience in biopharmaceutical innovation.
Citi acted as financial advisor to the Cell Design Labs in connection with the transaction.
About Cell Design Labs
Cell Design Labs is a biotherapeutics company that discovers and develops cell-based therapies. Using its proprietary technology platform for custom cell engineering, Cell Design Labs has been developing a portfolio of anticancer therapies. Initially focused on cancer, including both hematologic and solid tumors, this broad technology may also have applications in other complex diseases, such as autoimmune and degenerative disorders.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of people suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.
This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of Gilead and members of its senior management team. Forward-looking statements include, without limitation, statements regarding the business combination, its effect on Gilead’s revenues and earnings, the ability of the synNotch and Throttle technology platforms to accelerate Gilead’s development of next generation cellular therapy candidates; the ability of the technology platforms to complement Kite’s research and development efforts; the ability of Gilead to advance Cell Design Labs’ pre-clinical product candidates; the anticipated timing of clinical data; the possibility of unfavorable results from clinical trials; the expected timing of the completion of the transaction, the ability to complete the transaction in a timely manner or at all, difficulties or unanticipated expenses in connection with integrating the companies; and any assumptions underlying any of the foregoing. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Sung Lee, 650-524-7792
Amy Flood, 650-522-5643
Cell Design Labs
Angela Bitting, 925-202-6211
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
SquareWell Partners Officially Launches Today to Assist Companies in Navigating the Evolving Demands of Investors25.9.2018 09:00 | Tiedote
SquareWell’s unique approach, supported by its proprietary technology, was developed out of the founding partners’ recognition of the need to optimize company-investor engagement practices and support proactive management of environmental, social and governance (ESG) risks for maximum impact. Over the last 15 years, the prominence of ESG issues has risen dramatically in the capital markets and knowing what investors prioritize and how best to communicate with them remains a challenge for companies. Furthermore, activism is no longer just an investment strategy but has become a mainstream behavior. SquareWell acknowledges this changing dynamic and facilitates progress by providing companies with year-round strategic advice regarding their investors. With SquareWell’s support, companies are better able to anticipate and identify risks and opportunities associated with long-term strategic issues, ranging from capital allocation to supply chain oversight. By analyzing existing data and lev
FRISS Survey Reveals Big Bang of Digital Transformation in Insurance is Yet to Come25.9.2018 08:30 | Tiedote
Today, FRISS, the worldwide provider of AI powered fraud and risk solutions for the P&C insurance industry, released the “Digital Transformation in Insurance Survey 2018”. The survey was initiated to get a better understanding of the current market state, uncovering emerging global trends in P&C insurance regarding digital transformation. Over 170 insurance professionals participated, from various countries across the globe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005072/en/ FRISS launches Digital Transformation in Insurance Survey 2018 Digital transformation provides the insurance industry with the opportunity to use technology in order to improve efficiency, customer satisfaction and realize new strategic opportunities. These opportunities could create new services or business models and improved efficiency. Digitalization also opens doors to improve customer experience. However, digitalization can also result
AMPLEXOR a Gold Plus Sponsor of the 2018 NORDIC TechKomm in Copenhagen25.9.2018 08:03 | Tiedote
AMPLEXOR, a top-10 global language solutions provider, is a Gold Plus Sponsor and presenter at this year’s NORDIC TechKomm in Copenhagen on 26–27 September. This two-day event brings together experts from all over Europe to share best practices and present current ideas on the main conference topic, "How to make your documentation intelligent today." NORDIC TechKomm is geared toward professionals in technical communication eager to learn and share their knowledge about the latest industry trends. Attendees can expect to learn about creating effective and engaging content, ensuring documentation teams are self-sustainable, understanding the importance of AI and technical communication and more. At the 2018 NORDIC TechKomm, AMPLEXOR’s Manager of Strategic Accounts and augmented reality (AR) expert, Gilberto Picareta, will present, “Augmented Reality and Technical Authoring.” The presentation will discuss how AR is impacting technical information and communication, how to incorporate and
Veezi Signs Deal with CanalOlympia, Vivendi's Pan African Cinema Network25.9.2018 08:00 | Tiedote
Vista Group International (NZX & ASX: VGL) company Vista Entertainment Solutions (‘Vista Cinema’) and Vivendi’s CanalOlympia have signed an agreement to roll-out Vista Cinema’s Veezi across all their cinema venues. Veezi, already utilised by cinemas in 27 countries, is Vista Cinema’s SaaS cinema management solution for Independent cinemas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924006098/en/ Currently operating 9 venues across 7 countries, CanalOlympia is the leading network of cinema and live performance venues in Africa. Several additional sites are set to open in the months to come, extending the breadth of the CanalOlympia footprint. The CanalOlympia operation showcases the diversity of African culture and has helped bring cinemas back to countries currently short on entertainment choices and cultural infrastructure. The venues include the latest projection and sound technologies. They produce their own electr
Panasonic's Multi-hop HD-PLC Adopted as Smart Meter Communications System by Taiwan Power Company25.9.2018 07:27 | Tiedote
Panasonic Corporation has successfully proposed adoption to Taiwan Power Company of its HD-PLC (*1) high-speed power line communications technology as a communications system to utilize next-generation smart meters. Taiwan Power Company began accepting proposals for technology relating to communications systems in June 2017. Verification testing of the latest wireless technology and power line communications technology was held in Taipei City in September of that year. Smart meters will be introduced to approx. 260,000 households in main cities of Taiwan from December 2018. The HD-PLC technology meets the high performance criteria required, and smart meters incorporating this technology will be introduced in Taipei and other areas. Smart meters require stable communications performance to achieve detailed controls matching power demand with high-frequency data collection. The HD-PLC technology can meet these requirements and is expected to contribute to building IoT communications infr
IFF Announces Pricing of $1,500,000,000 Senior Notes Offering25.9.2018 01:25 | Tiedote
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF), a leading innovator of sensorial experiences that move the world, today announced that it has priced its public offering of $300,000,000 aggregate principal amount of its 3.400% senior notes due 2020, $400,000,000 aggregate principal amount of its 4.450% senior notes due 2028 and $800,000,000 aggregate principal amount of its 5.000% senior notes due 2048. IFF intends to use the net proceeds from the offering to pay a portion of the consideration for the previously announced merger with Frutarom Industries Ltd. and to pay related fees and expenses. IFF anticipates that the offering will close on September 26, 2018, subject to customary closing conditions. The offering is not contingent upon the consummation of the merger. If the closing of the merger has not occurred on or prior to February 7, 2019, or, if prior to such date, the merger agreement with Frutarom is terminated, IFF will be required t
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme